Developer docs
API playgroundTry for free, no card

Search company profiles

Singota Solutions

Full company profile

uuid0006fx3

Namestring
Singota Solutions
Websiteurl
singota.com
Company typeenum
Private
Founded yearint
2006
Descriptiontext

Singota Solutions is a private, U.S.-based contract drug development firm headquartered in Bloomington, Indiana, founded in 2006 by Alisa Kilgas, who continues to serve as Founder & CEO. The company operates in the contract development and manufacturing organization (CDMO) segment of the pharmaceutical services value chain, providing four integrated service lines: formulation development, analytical testing, aseptic manufacturing, and labeling. These capabilities position Singota to support drug developers — particularly those working on parenteral/injectable products requiring sterile fill-finish — across preclinical through clinical and small-scale commercial stages. With a headcount of 101–250 employees, the firm sits in the mid-size tier of U.S. CDMOs and is differentiated from larger peers by its regional, single-site footprint rather than by a global network of facilities.

The business model is service-based, typical of small-to-mid CDMOs: revenue is generated through project- and program-based contracts for formulation work, method development and validation, GMP analytical testing, aseptic fill-finish batches, and labeling/packaging activities. Customer relationships are likely structured around multi-phase programs with milestone or unit-based pricing rather than subscription or platform licensing models. The company's Bloomington location — outside the traditional Boston/New Jersey/Research Triangle CDMO corridors — suggests a regional commercial focus, though the source data does not disclose specific customer segments, named clients, geographic markets served, or pricing structure. No revenue, funding, ownership, or financial details were available in the provided sources, and the company website was inaccessible at time of data collection.

Strategically, the source material is thin on recent moves: no funding rounds, acquisitions, partnerships, leadership changes, product launches, regulatory milestones, or expansion announcements are documented. The single verifiable strategic action is the company's 2006 founding. Intangible assets (specialized sterile and analytical capabilities) and regulatory credentials from 18 years of GMP operations constitute the most defensible moat dimensions, while AI/ML capability is not evidenced in the data. Overall, the analytical picture is that of an established, founder-led mid-size CDMO with limited public information available for deeper investment scrutiny.

Short descriptiontext

Singota Solutions is a private Bloomington, Indiana-based contract drug development firm founded in 2006 that provides formulation development, analytical testing, aseptic manufacturing, and labeling services to pharmaceutical clients.

Ownership categoryenum
Headcount rangeband
51–100
akta.pro rankint
HeadquartersBloomington, United States
HQ citystring
Bloomington
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Keyword5 values
drug formulation development, aseptic fill-finish, analytical testing services, parenteral contract manufacturing, pharmaceutical labeling services
Industry5 codes
PRIMARYHLAAAKAB
Drug Product Fill-Finish & Aseptic Manufacturing Services
SECONDARYHLAGAGAG
Fill-Finish & Aseptic Drug Product Manufacturing (Biologics/ATMP)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Biopharma Manufacturing Services (Biologics/Cell & Gene)
SECONDARYHLAGADAB
Method Development & Validation (ICH/USP)
SECONDARYHLAGAHAL
GMP Scale-Up, Tech Transfer & Process Validation (PPQ)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/API & Small-Molecule Development/Manufacturing Services
SECONDARYHLAAAJAG
Aseptic Processing, Fill-Finish & Sterile Manufacturing Tech (isolators, lyophilization interfaces)
Healthcare & Life Sciences/Biotechnology & Biologics/Bioprocessing & Biomanufacturing Technology (upstream/downstream, single-use, analytics)
NAICS code2 codes
  • Pharmaceutical Preparation Manufacturing325412
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
SIC code2 codes
  • Services-Commercial Physical & Biological Research8731
  • Pharmaceutical Preparations2834
Product category
Pharmaceutical Contract Development and Manufacturing (CDMO)
Social media profiles1 record
Cost components6 values
Personnel, Operations, Infrastructure, Technology or R&D, Supply Chain, Marketing or Sales
GTM typeB2B
B2B
Offering typeServices
Services
Core offering1 text field

Singota Solutions is a contract drug development and manufacturing organization offering formulation development, analytical testing, aseptic making (sterile fill-finish), and labeling services for pharmaceutical and biotech clients. The firm supports drug product development from pre-clinical through clinical stages at its Bloomington, Indiana facility.

Differentiator
Functional benefit
Problem solved
Product and service4 records
1Formulation Development
CategoryPharmaceutical Contract Development
Description

Drug product formulation development services supporting pharmaceutical and biotech clients in developing sterile and parenteral dosage forms. Provided to drug developers requiring outsourced formulation expertise.

2Analytical Testing
CategoryPharmaceutical Contract Development
Description

Analytical testing services to support drug development and manufacturing release, providing quality and characterization data for pharmaceutical and biotech clients.

3Aseptic Making (Aseptic Fill-Finish)
CategoryPharmaceutical Contract Manufacturing
Description

Sterile aseptic fill-finish manufacturing services for injectable and parenteral drug products, supporting clinical and small-scale commercial supply for pharmaceutical and biotech sponsors.

4Labeling Services
CategoryPharmaceutical Contract Manufacturing
Description

Pharmaceutical labeling services providing clinical and commercial labeling of drug product units prepared through Singota's formulation and aseptic manufacturing workflows.

Recent move1 record

Each record includes

Date, Type, Title, Description, Source

Peers10 records
TypeEmerging player
Description

Specialty CDMO focused on formulation development, analytical services, and clinical supply for small-to-mid pharma and biotech — closely mirrors Singota's early-phase service mix and customer profile at similar scale.

TypeBroad incumbent
Description

European CDMO with sterile and aseptic manufacturing capabilities serving pharma and consumer health — comparable in development-through-commercial service stack to Singota, though with different geographic focus.

3Recipharm
TypeBroad incumbent
Description

European-headquartered CDMO offering sterile fill-finish, formulation development, and analytical services across small molecules and biologics — competes with Singota for injectable and clinical supply programs.

TypeBroad incumbent
Description

Through its Patheon CDMO business, Thermo Fisher offers end-to-end pharmaceutical development and sterile manufacturing at global scale — overlapping with Singota's formulation, analytical, and aseptic fill services.

TypeBroad incumbent
Description

Germany-based specialist in aseptic fill-finish of injectable drugs, including complex biologics and ophthalmics — a benchmark for sterile injectable CDMO capability that competes for the same clinical and commercial sponsors.

TypeBroad incumbent
Description

Global large-molecule and small-molecule CDMO with significant clinical and commercial sterile fill-finish capacity across biologics and injectables — sets the competitive benchmark Singota is benchmarked against on flexibility and turnaround.

TypeDirect peer
Description

US-based mid-sized CDMO offering sterile fill-finish, analytical development, and formulation services to small and mid-cap pharma — directly comparable scale and service mix to Singota.

TypeDirect peer
Description

UK-based specialist CDMO focused on aseptic vial filling and lyophilization for clinical trials. Highly comparable in service scope (clinical sterile fill-finish) though geographically focused on European sponsors.

TypeBroad incumbent
Description

Global CDMO with strong sterile fill-finish, lyophilization, and clinical supply services; absorbed LSNE in 2021. Competes with Singota across clinical-stage injectable manufacturing and packaging.

TypeDirect peer
Description

Specialty CDMO historically focused on aseptic fill-finish and lyophilization for clinical-stage injectables and biologics — the closest comparable to Singota in modality, batch size, and customer segment. Now operates within PCI Pharma Services.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat3 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights5 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles1 record

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Singota Solutions

Pharmaceutical Contract Development and Manufacturing (CDMO)singota.com

Singota Solutions is a private Bloomington, Indiana-based contract drug development firm founded in 2006 that provides formulation development, analytical testing, aseptic manufacturing, and labeling services to pharmaceutical clients.

What Singota Solutions does

Singota Solutions is a private, U.S.-based contract drug development firm headquartered in Bloomington, Indiana, founded in 2006 by Alisa Kilgas, who continues to serve as Founder & CEO. The company operates in the contract development and manufacturing organization (CDMO) segment of the pharmaceutical services value chain, providing four integrated service lines: formulation development, analytical testing, aseptic manufacturing, and labeling. These capabilities position Singota to support drug developers — particularly those working on parenteral/injectable products requiring sterile fill-finish — across preclinical through clinical and small-scale commercial stages. With a headcount of 101–250 employees, the firm sits in the mid-size tier of U.S. CDMOs and is differentiated from larger peers by its regional, single-site footprint rather than by a global network of facilities.

The business model is service-based, typical of small-to-mid CDMOs: revenue is generated through project- and program-based contracts for formulation work, method development and validation, GMP analytical testing, aseptic fill-finish batches, and labeling/packaging activities. Customer relationships are likely structured around multi-phase programs with milestone or unit-based pricing rather than subscription or platform licensing models. The company's Bloomington location — outside the traditional Boston/New Jersey/Research Triangle CDMO corridors — suggests a regional commercial focus, though the source data does not disclose specific customer segments, named clients, geographic markets served, or pricing structure. No revenue, funding, ownership, or financial details were available in the provided sources, and the company website was inaccessible at time of data collection.

Strategically, the source material is thin on recent moves: no funding rounds, acquisitions, partnerships, leadership changes, product launches, regulatory milestones, or expansion announcements are documented. The single verifiable strategic action is the company's 2006 founding. Intangible assets (specialized sterile and analytical capabilities) and regulatory credentials from 18 years of GMP operations constitute the most defensible moat dimensions, while AI/ML capability is not evidenced in the data. Overall, the analytical picture is that of an established, founder-led mid-size CDMO with limited public information available for deeper investment scrutiny.

Singota Solutions firmographics

Firmographics
Name
Singota Solutions
Website
https://singota.com
Company type
Private
Founded year
2006
Headcount range
51–100 employees
Short description
Singota Solutions is a private Bloomington, Indiana-based contract drug development firm founded in 2006 that provides formulation development, analytical testing, aseptic manufacturing, and labeling services to pharmaceutical clients.
Ownership category
akta.pro rank

Singota Solutions industry classification

Industry
Product category
Pharmaceutical Contract Development and Manufacturing (CDMO)
NAICS
Pharmaceutical Preparation Manufacturing (325412), Research and Development in Biotechnology (except Nanobiotechnology) (541714)
SIC
Services-Commercial Physical & Biological Research (8731), Pharmaceutical Preparations (2834)
akta.pro industry
PRIMARYHLAAAKAB
Drug Product Fill-Finish & Aseptic Manufacturing Services
SECONDARYHLAGAGAG
Fill-Finish & Aseptic Drug Product Manufacturing (Biologics/ATMP)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Biopharma Manufacturing Services (Biologics/Cell & Gene)
SECONDARYHLAGADAB
Method Development & Validation (ICH/USP)
SECONDARYHLAGAHAL
GMP Scale-Up, Tech Transfer & Process Validation (PPQ)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/API & Small-Molecule Development/Manufacturing Services
SECONDARYHLAAAJAG
Aseptic Processing, Fill-Finish & Sterile Manufacturing Tech (isolators, lyophilization interfaces)
Healthcare & Life Sciences/Biotechnology & Biologics/Bioprocessing & Biomanufacturing Technology (upstream/downstream, single-use, analytics)

Keywords

  • Drug formulation development
  • Aseptic fill-finish
  • Analytical testing services
  • Parenteral contract manufacturing
  • Pharmaceutical labeling services

Where Singota Solutions is headquartered

Location

Headquarters

HQ city
Bloomington
HQ country
United States
HQ region
North America

Markets served

Singota Solutions business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Operations, Infrastructure, Technology or R&D, Supply Chain, Marketing or Sales

Singota Solutions product offering

Product offering

Core offering

Singota Solutions is a contract drug development and manufacturing organization offering formulation development, analytical testing, aseptic making (sterile fill-finish), and labeling services for pharmaceutical and biotech clients. The firm supports drug product development from pre-clinical through clinical stages at its Bloomington, Indiana facility.

Differentiator

Problem solved

Functional benefit

Products and services

  • Formulation Development Drug product formulation development services supporting pharmaceutical and biotech clients in developing sterile and parenteral dosage forms. Provided to drug developers requiring outsourced formulation expertise.
  • Analytical Testing Analytical testing services to support drug development and manufacturing release, providing quality and characterization data for pharmaceutical and biotech clients.
  • Aseptic Making (Aseptic Fill-Finish) Sterile aseptic fill-finish manufacturing services for injectable and parenteral drug products, supporting clinical and small-scale commercial supply for pharmaceutical and biotech sponsors.
  • Labeling Services Pharmaceutical labeling services providing clinical and commercial labeling of drug product units prepared through Singota's formulation and aseptic manufacturing workflows.

Companies that use Singota Solutions

Customer profile

Ideal customer profiles1 record

Singota Solutions technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Singota Solutions partnerships and signals

Strategic signal

Recent moves1 record

Singota Solutions competitors and assessment

Company assessment

Emerging players

  • Ardena: Specialty CDMO focused on formulation development, analytical services, and clinical supply for small-to-mid pharma and biotech — closely mirrors Singota's early-phase service mix and customer profile at similar scale.

Broad incumbents

  • Aenova Group: European CDMO with sterile and aseptic manufacturing capabilities serving pharma and consumer health — comparable in development-through-commercial service stack to Singota, though with different geographic focus.
  • Recipharm: European-headquartered CDMO offering sterile fill-finish, formulation development, and analytical services across small molecules and biologics — competes with Singota for injectable and clinical supply programs.
  • Thermo Fisher Scientific (Patheon): Through its Patheon CDMO business, Thermo Fisher offers end-to-end pharmaceutical development and sterile manufacturing at global scale — overlapping with Singota's formulation, analytical, and aseptic fill services.
  • Vetter Pharma: Germany-based specialist in aseptic fill-finish of injectable drugs, including complex biologics and ophthalmics — a benchmark for sterile injectable CDMO capability that competes for the same clinical and commercial sponsors.
  • Catalent: Global large-molecule and small-molecule CDMO with significant clinical and commercial sterile fill-finish capacity across biologics and injectables — sets the competitive benchmark Singota is benchmarked against on flexibility and turnaround.
  • PCI Pharma Services: Global CDMO with strong sterile fill-finish, lyophilization, and clinical supply services; absorbed LSNE in 2021. Competes with Singota across clinical-stage injectable manufacturing and packaging.

Direct peers

  • Alcami Corporation: US-based mid-sized CDMO offering sterile fill-finish, analytical development, and formulation services to small and mid-cap pharma — directly comparable scale and service mix to Singota.
  • Symbiosis Pharmaceutical Services: UK-based specialist CDMO focused on aseptic vial filling and lyophilization for clinical trials. Highly comparable in service scope (clinical sterile fill-finish) though geographically focused on European sponsors.
  • LSNE (Lyophilization Services of New England): Specialty CDMO historically focused on aseptic fill-finish and lyophilization for clinical-stage injectables and biologics — the closest comparable to Singota in modality, batch size, and customer segment. Now operates within PCI Pharma Services.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat3 records

Key risks5 records

Key highlights5 records

Customer concentration

Singota Solutions social profiles

Digital presence

Singota Solutions financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Singota Solutions leadership team

Management profile

Number of profiles

Profiles1 record

Singota Solutions funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Singota Solutions M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Singota Solutions

What does Singota Solutions do?

Singota Solutions is a contract drug development and manufacturing organization offering formulation development, analytical testing, aseptic making (sterile fill-finish), and labeling services for pharmaceutical and biotech clients. The firm supports drug product development from pre-clinical through clinical stages at its Bloomington, Indiana facility.

When was Singota Solutions founded?

Singota Solutions was founded in 2006. It employs 51 to 100 people.

Where is Singota Solutions based?

Singota Solutions is headquartered in Bloomington, United States, in the North America region.

Who are Singota Solutions's main competitors?

Ardena is listed as an emerging player. Broad incumbents are Aenova Group, Recipharm, Thermo Fisher Scientific (Patheon), Vetter Pharma, Catalent and PCI Pharma Services. Direct peers are Alcami Corporation, Symbiosis Pharmaceutical Services and LSNE (Lyophilization Services of New England).

Does Singota Solutions have an API?

No public API is recorded for Singota Solutions.

What industry is Singota Solutions in?

Singota Solutions's product category is Pharmaceutical Contract Development and Manufacturing (CDMO). Its primary akta.pro industry code is HLAAAKAB, Drug Product Fill-Finish & Aseptic Manufacturing Services, with a secondary code of HLAGAGAG, Fill-Finish & Aseptic Drug Product Manufacturing (Biologics/ATMP). Its NAICS code is 325412 and its SIC code is 8731.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals